Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29228692 | 0.96 | FPR2 (0.62) | LDHAFPR2KMT2AHDAC8PPARG | |
| SCHEMBL30872672 | 0.96 | FPR2 (0.62) | LDHAFPR2KMT2AHDAC8PPARG | |
| SCHEMBL6921340 | 0.88 | GAA (0.58) | LDHAKMT2ACA2ALDH1A1NPC1 | |
| SCHEMBL1177224 | 0.88 | PDCD1 (0.56) | LDHAKMT2AHDAC8PPARGFFAR1 | |
| SCHEMBL16116802 | 0.88 | LDHA (0.63) | LDHAFPR2KMT2APPARGCA2 | |
| SCHEMBL1177223 | 0.88 | PDCD1 (0.56) | LDHAKMT2AHDAC8PPARGFFAR1 | |
| SCHEMBL839542 | 0.88 | LDHA (0.63) | LDHAFPR2KMT2APPARGCA2 | |
| SCHEMBL1177136 | 0.88 | PDCD1 (0.56) | LDHAKMT2AHDAC8PPARGFFAR1 | |
| SCHEMBL28382375 | 0.86 | LDHA (0.61) | LDHAFPR2KMT2APPARGCA2 | |
| SCHEMBL1760907 | 0.86 | LDHA (0.53) | LDHAKMT2AHDAC8PPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | LDHA 1031/4885FPR2 3091/4885KMT2A 3747/4885 |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, SLC16A1, FH | LDHA 959/4885FPR2 347/4885KMT2A 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.